Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

被引：4

作者：

Zelenetz, Andrew D. ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Ribrag, Vincent ^{[3
]}

Linton, Kim M. ^{[4
,5
]}

Collins, Graham P. ^{[6
]}

Bishton, Mark ^{[7
]}

Lopez Jimenez, Javier ^{[8
]}

Dholaria, Bhagirathbhai ^{[9
]}

Mengarelli, Andrea ^{[10
]}

Phillips, Tycel J. ^{[11
]}

Sungala, Nagendra Prasad ^{[12
]}

Chan, Henry ^{[13
]}

Musuraca, Gerardo ^{[14
]}

Sheehy, Oonagh ^{[15
]}

Yan, Junyi ^{[16
]}

Xu, Weiming ^{[16
]}

Azoulay, Michel ^{[17
]}

Zinzani, Pier Luigi ^{[18
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[3] Gustave Roussy Canc Campus, Villejuif, France

[4] Christie NHS Fdn Trust, Manchester, Lancs, England

[5] Manchester Canc Res Ctr, Manchester, Lancs, England

[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England

[7] Nottingham Univ Hosp, Nottingham, England

[8] Hosp Univ Ramon y Cajal, Hematol Serv, Madrid, Spain

[9] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA

[10] Regina Elena Inst Canc Res, Rome, Italy

[11] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA

[12] Liverpool Hosp, Dept Haematol, Sydney, NSW, Australia

[13] North Shore Hosp, Auckland, New Zealand

[14] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy

[15] Belfast HSC Trust, Belfast, Antrim, North Ireland

[16] MEI Pharma Inc, San Diego, CA USA

[17] Kyowa Kirin Co, Princeton, NJ USA

[18] Univ Bologna, Inst Hematol Seregnoli, Bologna, Italy

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165409

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3595 / 3597

页数：3

共 50 条

[1] Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.
Zelenetz, Andrew David
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collins, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Phillips, Tycel Jovelle
Musuraca, Gerardo
Sheehy, Oonagh
Li, Joanne
Xu, Weiming
Azoulay, Michel Meyer
Ghalie, Richard
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
Phillips, Tycel
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collin, Graham P.
Lopez-Jimenez, Javier
Reddy, Nishitha
Mengarelli, Andrea
Musuraca, Gerardo
Sheehy, Oonagh
Xu, Weiming
Azoulay, Michel
Ghalie, Richard G.
Zinzani, Pier Luigi
Zelenetz, Andrew D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S387 - S388
[3] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
Schuster, Stephen J.
Dickinson, Michael
Dreyling, Martin
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter
Zia, Aiesha
Morisse, Mony Chenda
Fowler, Nathan Hale
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
[4] The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
Zelenetz, Andrew D.
Jurczak, Wojciech
Ribrag, Vincent
Linton, Kim
Collins, Graham P.
Jimenez, Javier L.
Bishton, Mark
Dholaria, Bhagirathbhai
Mengarelli, Andrea
Phillips, Tycel J.
Sungala, Nagendraprasad
Musuraca, Gerardo
Sheehy, Oonagh
Van Den Neste, Eric
Odera, Mitsuhiko
Miao, Lu
Gold, Daniel P.
Ghalie, Richard G.
Zinzani, Pier L.
HEMASPHERE, 2024, 8 (08):
[5] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
Borchmann, Peter
Morschhauser, Franck
Dahiya, Saurabh
Palomba, M. Lia
Garcia-Sancho, Alejandro Martin
Reguera Ortega, Juan Luis
Kuruvilla, John
Jaeger, Ulrich
Cartron, Guillaume
Izutsu, Koji
Dreyling, Martin
Kahl, Brad
Ghesquieres, Herve
Ardeshna, Kirit
Goto, Hideki
Barbui, Anna Maria
Abramson, Jeremy S.
Fleury, Isabelle
Mielke, Stephan
Farazi, Thalia
Fasan, Omotayo
Lymp, James
Vedal, Min
Nishii, Rina
Avilion, Ariel
Papuga, Jessica
Nastoupil, Loretta J.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
[6] Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
Soumerai, Jacob D.
Diefenbach, Catherine S.
Samaniego, Felipe
Kumar, Abhijeet
Tsai, Michaela L.
Asch, Adam S.
Jagadeesh, Deepa
Kenkre, Vaishalee P.
Lossos, Izidore S.
Salman, Huda
Awan, Farrukh T.
Miao, Lu
Ghalie, Richard G.
Zelenetz, Andrew D.
BLOOD, 2022, 140
[7] Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, Nancy L.
Costello, Brian A.
LaPlant, Betsy R.
Ansell, Stephen M.
Kuruvilla, John G.
Reeder, Craig B.
Thye, Lim S.
Anderson, Daniel M.
Krysiak, Kilannin
Ramirez, Cody
Qi, Jing
Siegel, Barry A.
Griffith, Malachi
Griffith, Obi L.
Gomez, Felicia
Fehniger, Todd A.
BLOOD, 2018, 131 (02) : 182 - 190
[8] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Chong, Geoffrey
Taszner, Michal
Novelli, Silvana
Cho, Seok-Goo
Villasboas, Jose C.
Ubieto, Ana Jimenez
Tessoulin, Benoit
Poon, Michelle
Tucker, David
Walewski, Jan
Song, Yuqin
Bachy, Emmanuel
Guidez, Stephanie
Alonso, Aranzazu
Jagadeesh, Deepa
Luminari, Stefano
Mayer, Laura Magnano
Iskierka-Jazdzewska, Elzbieta
Tani, Monica
Cai, Jingxian
Uppala, Amulya
Shariff, Saleem
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Kim, Tae Min
CANCER RESEARCH, 2024, 84 (07)
[9] Efficacy and safety of Tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial
Schuster, S.
Dickinson, M.
Dreyling, M.
Martinez-Lopez, J.
Kolstad, A.
Butler, J.
Ghosh, M.
Popplewell, L.
Chavez, J.
Bachy, E.
Kato, K.
Harigae, H.
Kersten, M. J.
Andreadis, C.
Riedell, P.
Zia, A.
Morisse, M. C.
Fowler, N. H.
Thieblemont, C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 104 - 105
[10] ELARA: A phase II, single-arm, multicenter, open label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with refractory/relapsed follicular lymphoma (r/r FL).
Dickinson, Michael
Popplewell, Leslie
Kolstad, Arne
Ho, Joy
Teshima, Takanori
Dreyling, Martin H.
Schuster, Stephen J.
Thieblemont, Catherine
Yateman, Nigel
Lehnhoff, Katja
Lawniczek, Tomasz
Bubuteishvili-Pacaud, Lida
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →